MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) --IGM Biosciences, Inc.. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi US to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.

加利福尼亚州山景城，2024年4月17日（环球通讯社）--创建和开发工程化IGM抗体的临床阶段生物技术公司IGM Biosciences，Inc.（Nasdaq:IGMS）今天宣布，该公司与赛诺菲美国签订的创建和开发IGM激动剂抗体的独家全球合作协议现在将专注于免疫学/炎症靶标。

IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration..

IGM将保留其与赛诺菲在合作下提名的肿瘤学目标相关的专有技术的全球权利。。

“We are very pleased with our collaboration with Sanofi and with the preclinical data that we have generated in both the immunology/inflammation and the oncology portions of the collaboration,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “As we assess next steps with respect to these oncology targets, our top internal priorities remain our clinical-stage oncology and autoimmune programs.”.

IGM Biosciences首席执行官弗雷德·施瓦泽（FredSchwarzer）表示：“我们对与赛诺菲的合作以及在合作的免疫学/炎症和肿瘤学部分产生的临床前数据感到非常满意。”。“当我们评估这些肿瘤学目标的下一步时，我们内部的首要任务仍然是我们的临床阶段肿瘤学和自身免疫计划。”。

Terms of the Collaboration

合作条款

As previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research and development activities and assume related costs through the completion of a Phase 1 clinical trial for up to two constructs directed to each target, after which Sanofi will be responsible for all future development and commercialization activities and associated costs.

如前所述，根据合作协议的条款，对于赛诺菲指定的三个免疫学/炎症目标中的每一个，IGM将领导研究和开发活动，并通过完成针对每个目标的多达两个构建体的第一阶段临床试验来承担相关成本，之后赛诺菲将负责所有未来的开发和商业化活动以及相关成本。

IGM will be eligible to receive up to $1,065 million in aggregate development, regulatory and commercial milestones per target as well as tiered high single-digit to low-teen royalties on global net sales..

IGM将有资格获得每个目标总计10.65亿美元的开发、监管和商业里程碑，以及全球净销售额从高个位数到低青少年的分层版税。。

About IGM Biosciences, Inc.

关于IGM Biosciences，Inc。

IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgM antibodies with only 2 binding sites.

IGM Biosciences是一家临床阶段生物技术公司，致力于开发和提供一类新型药物，用于治疗癌症、自身免疫性疾病和炎症性疾病。IGM的临床和临床前资产管道基于IGM抗体，与仅具有2个结合位点的常规IGM抗体相比，IGM抗体具有10个结合位点。

IGM also has an exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies against immunology and inflammation targets. For more information, please visit www.igmbio.com..

IGM还与赛诺菲签订了独家全球合作协议，以创建和开发针对免疫学和炎症靶标的IGM激动剂抗体。有关更多信息，请访问www.igmbio.com。